{"id":815893,"date":"2025-02-20T16:19:38","date_gmt":"2025-02-20T21:19:38","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/aurinia-pharmaceuticals-to-release-2024-fourth-quarter-and-full-year-financial-and-operational-results-on-february-27-2025\/"},"modified":"2025-02-20T16:19:38","modified_gmt":"2025-02-20T21:19:38","slug":"aurinia-pharmaceuticals-to-release-2024-fourth-quarter-and-full-year-financial-and-operational-results-on-february-27-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/aurinia-pharmaceuticals-to-release-2024-fourth-quarter-and-full-year-financial-and-operational-results-on-february-27-2025\/","title":{"rendered":"Aurinia Pharmaceuticals to Release 2024 Fourth Quarter and Full Year Financial and Operational Results on February 27, 2025"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Aurinia Pharmaceuticals to Release 2024 Fourth Quarter and Full Year Financial and Operational Results on February 27, 2025<\/b><\/p>\n<p>ROCKVILLE, Md. &amp; EDMONTON, Alberta&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nAurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release 2024 fourth quarter and full year financial and operational results before markets open on February 27, 2025.\n<\/p>\n<p>\nAurinia\u2019s management team will host a conference call and webcast at 8:30 am ET that day to review these results and provide a general business update. The link to the audio webcast is available <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.auriniapharma.com%2Finvestors-and-media%2Fnews-events%2Fir-calendar&amp;esheet=54211150&amp;newsitemid=20250220370017&amp;lan=en-US&amp;anchor=here&amp;index=1&amp;md5=d6908c68cd396291f41a136c24a3ad08\">here<\/a>. To join the conference call, please dial 877-407-9170\/+1 201-493-6756. A replay of the webcast will be available on Aurinia\u2019s website.\n<\/p>\n<p><b>About Aurinia<\/b><\/p>\n<p>\nAurinia Pharmaceuticals is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS\u00ae (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. Aurinia is also developing AUR200, a dual B cell activating factor (BAFF) and a proliferation inducing ligand (APRIL) inhibitor for the potential treatment of autoimmune diseases.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250220370017r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20250220370017\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20250220370017\/en\/<\/a><\/span><\/p>\n<p><b>Media &amp; Investor Inquiries:<br \/>\n<\/b><br \/>Andrea Christopher<br \/>\n<br \/>Corporate Communications &amp; Investor Relations<br \/>\n<br \/>Aurinia Pharmaceuticals Inc.<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:achristopher@auriniapharma.com\"><b>achristopher@auriniapharma.com<br \/>\n<\/b><\/a><\/p>\n<p><b>General Investor Inquiries:<br \/>\n<\/b><br \/><a rel=\"nofollow\" href=\"mailto:ir@auriniapharma.com\"><b>ir@auriniapharma.com<\/b><\/a><\/p>\n<p><b>KEYWORDS:<\/b> United States North America Canada Maryland<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Health Infectious Diseases Research Pharmaceutical Science Biotechnology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20250220370017\/en\/2388239\/3\/aurina_logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Aurinia Pharmaceuticals to Release 2024 Fourth Quarter and Full Year Financial and Operational Results on February 27, 2025 ROCKVILLE, Md. &amp; EDMONTON, Alberta&#8211;(BUSINESS WIRE)&#8211; Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release 2024 fourth quarter and full year financial and operational results before markets open on February 27, 2025. Aurinia\u2019s management team will host a conference call and webcast at 8:30 am ET that day to review these results and provide a general business update. The link to the audio webcast is available here. To join the conference call, please dial 877-407-9170\/+1 201-493-6756. A replay of the webcast will be available on Aurinia\u2019s website. About Aurinia Aurinia Pharmaceuticals is a biopharmaceutical company focused &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aurinia-pharmaceuticals-to-release-2024-fourth-quarter-and-full-year-financial-and-operational-results-on-february-27-2025\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Aurinia Pharmaceuticals to Release 2024 Fourth Quarter and Full Year Financial and Operational Results on February 27, 2025&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-815893","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Aurinia Pharmaceuticals to Release 2024 Fourth Quarter and Full Year Financial and Operational Results on February 27, 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aurinia-pharmaceuticals-to-release-2024-fourth-quarter-and-full-year-financial-and-operational-results-on-february-27-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aurinia Pharmaceuticals to Release 2024 Fourth Quarter and Full Year Financial and Operational Results on February 27, 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Aurinia Pharmaceuticals to Release 2024 Fourth Quarter and Full Year Financial and Operational Results on February 27, 2025 ROCKVILLE, Md. &amp; EDMONTON, Alberta&#8211;(BUSINESS WIRE)&#8211; Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release 2024 fourth quarter and full year financial and operational results before markets open on February 27, 2025. Aurinia\u2019s management team will host a conference call and webcast at 8:30 am ET that day to review these results and provide a general business update. The link to the audio webcast is available here. To join the conference call, please dial 877-407-9170\/+1 201-493-6756. A replay of the webcast will be available on Aurinia\u2019s website. About Aurinia Aurinia Pharmaceuticals is a biopharmaceutical company focused &hellip; Continue reading &quot;Aurinia Pharmaceuticals to Release 2024 Fourth Quarter and Full Year Financial and Operational Results on February 27, 2025&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/aurinia-pharmaceuticals-to-release-2024-fourth-quarter-and-full-year-financial-and-operational-results-on-february-27-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-20T21:19:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250220370017r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aurinia-pharmaceuticals-to-release-2024-fourth-quarter-and-full-year-financial-and-operational-results-on-february-27-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aurinia-pharmaceuticals-to-release-2024-fourth-quarter-and-full-year-financial-and-operational-results-on-february-27-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Aurinia Pharmaceuticals to Release 2024 Fourth Quarter and Full Year Financial and Operational Results on February 27, 2025\",\"datePublished\":\"2025-02-20T21:19:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aurinia-pharmaceuticals-to-release-2024-fourth-quarter-and-full-year-financial-and-operational-results-on-february-27-2025\\\/\"},\"wordCount\":250,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aurinia-pharmaceuticals-to-release-2024-fourth-quarter-and-full-year-financial-and-operational-results-on-february-27-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250220370017r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aurinia-pharmaceuticals-to-release-2024-fourth-quarter-and-full-year-financial-and-operational-results-on-february-27-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aurinia-pharmaceuticals-to-release-2024-fourth-quarter-and-full-year-financial-and-operational-results-on-february-27-2025\\\/\",\"name\":\"Aurinia Pharmaceuticals to Release 2024 Fourth Quarter and Full Year Financial and Operational Results on February 27, 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aurinia-pharmaceuticals-to-release-2024-fourth-quarter-and-full-year-financial-and-operational-results-on-february-27-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aurinia-pharmaceuticals-to-release-2024-fourth-quarter-and-full-year-financial-and-operational-results-on-february-27-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250220370017r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2025-02-20T21:19:38+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aurinia-pharmaceuticals-to-release-2024-fourth-quarter-and-full-year-financial-and-operational-results-on-february-27-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aurinia-pharmaceuticals-to-release-2024-fourth-quarter-and-full-year-financial-and-operational-results-on-february-27-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aurinia-pharmaceuticals-to-release-2024-fourth-quarter-and-full-year-financial-and-operational-results-on-february-27-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250220370017r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250220370017r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aurinia-pharmaceuticals-to-release-2024-fourth-quarter-and-full-year-financial-and-operational-results-on-february-27-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aurinia Pharmaceuticals to Release 2024 Fourth Quarter and Full Year Financial and Operational Results on February 27, 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Aurinia Pharmaceuticals to Release 2024 Fourth Quarter and Full Year Financial and Operational Results on February 27, 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/aurinia-pharmaceuticals-to-release-2024-fourth-quarter-and-full-year-financial-and-operational-results-on-february-27-2025\/","og_locale":"en_US","og_type":"article","og_title":"Aurinia Pharmaceuticals to Release 2024 Fourth Quarter and Full Year Financial and Operational Results on February 27, 2025 - Market Newsdesk","og_description":"Aurinia Pharmaceuticals to Release 2024 Fourth Quarter and Full Year Financial and Operational Results on February 27, 2025 ROCKVILLE, Md. &amp; EDMONTON, Alberta&#8211;(BUSINESS WIRE)&#8211; Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release 2024 fourth quarter and full year financial and operational results before markets open on February 27, 2025. Aurinia\u2019s management team will host a conference call and webcast at 8:30 am ET that day to review these results and provide a general business update. The link to the audio webcast is available here. To join the conference call, please dial 877-407-9170\/+1 201-493-6756. A replay of the webcast will be available on Aurinia\u2019s website. About Aurinia Aurinia Pharmaceuticals is a biopharmaceutical company focused &hellip; Continue reading \"Aurinia Pharmaceuticals to Release 2024 Fourth Quarter and Full Year Financial and Operational Results on February 27, 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/aurinia-pharmaceuticals-to-release-2024-fourth-quarter-and-full-year-financial-and-operational-results-on-february-27-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-20T21:19:38+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250220370017r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aurinia-pharmaceuticals-to-release-2024-fourth-quarter-and-full-year-financial-and-operational-results-on-february-27-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aurinia-pharmaceuticals-to-release-2024-fourth-quarter-and-full-year-financial-and-operational-results-on-february-27-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Aurinia Pharmaceuticals to Release 2024 Fourth Quarter and Full Year Financial and Operational Results on February 27, 2025","datePublished":"2025-02-20T21:19:38+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aurinia-pharmaceuticals-to-release-2024-fourth-quarter-and-full-year-financial-and-operational-results-on-february-27-2025\/"},"wordCount":250,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aurinia-pharmaceuticals-to-release-2024-fourth-quarter-and-full-year-financial-and-operational-results-on-february-27-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250220370017r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aurinia-pharmaceuticals-to-release-2024-fourth-quarter-and-full-year-financial-and-operational-results-on-february-27-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/aurinia-pharmaceuticals-to-release-2024-fourth-quarter-and-full-year-financial-and-operational-results-on-february-27-2025\/","name":"Aurinia Pharmaceuticals to Release 2024 Fourth Quarter and Full Year Financial and Operational Results on February 27, 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aurinia-pharmaceuticals-to-release-2024-fourth-quarter-and-full-year-financial-and-operational-results-on-february-27-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aurinia-pharmaceuticals-to-release-2024-fourth-quarter-and-full-year-financial-and-operational-results-on-february-27-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250220370017r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2025-02-20T21:19:38+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aurinia-pharmaceuticals-to-release-2024-fourth-quarter-and-full-year-financial-and-operational-results-on-february-27-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/aurinia-pharmaceuticals-to-release-2024-fourth-quarter-and-full-year-financial-and-operational-results-on-february-27-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aurinia-pharmaceuticals-to-release-2024-fourth-quarter-and-full-year-financial-and-operational-results-on-february-27-2025\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250220370017r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250220370017r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aurinia-pharmaceuticals-to-release-2024-fourth-quarter-and-full-year-financial-and-operational-results-on-february-27-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Aurinia Pharmaceuticals to Release 2024 Fourth Quarter and Full Year Financial and Operational Results on February 27, 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/815893","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=815893"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/815893\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=815893"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=815893"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=815893"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}